<!DOCTYPE html>
<html lang="en">
    <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
        <title>17</title>

        <link href="bootstrap.min.css" rel="stylesheet">
        <link href="custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="treatments.css" rel="stylesheet" type="text/css"/>
        <link href="recreated_tables.css" rel="stylesheet" type="text/css"/>
           <style>
        .sep {
            border-bottom:1px solid lightgray;
        }
        .sep td {
            padding-bottom:5px;
            padding-top:5px;
        }
        br {
            display: block;
            margin-top: 5px 0;
        }
    </style>
    </head>
    <body>
        <div class="container"><p>As dual therapy, ceftriaxone and azithromycin should be administered together on the same day, preferably simultaneously and under direct observation. Ceftriaxone in a single injection of 250 mg provides sustained, high bactericidal levels in the blood. Extensive clinical experience indicates that ceftriaxone is safe and effective for the treatment of uncomplicated gonorrhea at all anatomic sites, curing 99.2% of uncomplicated urogenital and anorectal and 98.9% of pharyngeal infections in clinical trials <sup id="fnref:566"><a class="footnote-ref" href="#fn:566" rel="footnote">1</a></sup>  <sup id="fnref:567"><a class="footnote-ref" href="#fn:567" rel="footnote">2</a></sup>. No clinical or pharmacodynamic data exist to support use of doses of ceftriaxone &gt;250 mg. </p>
<p>Single-dose injectable cephalosporin regimens (other than ceftriaxone 250 mg IM) that are safe and generally effective against uncomplicated urogenital and anorectal gonococcal infections include ceftizoxime (500 mg IM), cefoxitin (2 g IM with probenecid 1 g orally), and cefotaxime (500 mg IM). None of these injectable cephalosporins offer any advantage over ceftriaxone for urogenital infection, and efficacy for pharyngeal infection is less certain <sup id="fnref2:566"><a class="footnote-ref" href="#fn:566" rel="footnote">1</a></sup>  <sup id="fnref2:567"><a class="footnote-ref" href="#fn:567" rel="footnote">2</a></sup>. Several other antimicrobials are active against <em>N. gonorrhoeae</em>, but none have substantial advantages over the recommended regimen, and efficacy data (especially for pharyngeal infection) are limited.</p>
<p>A 400-mg oral dose of cefixime should only be considered as an alternative cephalosporin regimen because it does not provide as high, nor as sustained, bactericidal blood levels as a 250-mg dose of ceftriaxone; further, it demonstrates limited efficacy for treatment of pharyngeal gonorrhea (92.3% cure, 95% CI=74.9%-99.1%); in older clinical studies, cefixime cured 97.5% of uncomplicated urogenital and anorectal gonococcal infections (95% CI=95.4%-99.8%) <sup id="fnref3:566"><a class="footnote-ref" href="#fn:566" rel="footnote">1</a></sup>  <sup id="fnref3:567"><a class="footnote-ref" href="#fn:567" rel="footnote">2</a></sup>. The increase in the prevalence of isolates obtained through GISP with elevated cefixime MICs might indicate early stages of development of clinically significant gonococcal resistance to cephalosporins. CDC anticipates that rising cefixime MICs soon will result in declining effectiveness of cefixime for the treatment of urogenital gonorrhea. Furthermore, as cefixime becomes less effective, continued used of cefixime might hasten the development of resistance to ceftriaxone, a safe, well-tolerated, injectable cephalosporin and the last antimicrobial that is known to be highly effective in a single dose for treatment of gonorrhea at all anatomic sites of infection. Other oral cephalosporins (e.g., cefpodoxime and cefuroxime) are not recommended because of inferior efficacy and less favorable pharmacodynamics <sup id="fnref4:566"><a class="footnote-ref" href="#fn:566" rel="footnote">1</a></sup>  <sup id="fnref:568"><a class="footnote-ref" href="#fn:568" rel="footnote">3</a></sup>.</p>
<p>Because of the prevalence of tetracycline resistance among GISP isolates, particularly those with elevated cefixime MICs <sup id="fnref:118"><a class="footnote-ref" href="#fn:118" rel="footnote">4</a></sup>, the use of azithromycin as the second antimicrobial is preferred. However, in the case of azithromycin allergy, doxycycline (100 mg orally twice a day for 7 days) can be used in place of azithromycin as an alternative second antimicrobial when used in combination with ceftriaxone or cefixime.</p>
<p>In a recent clinical trial, dual treatment of uncomplicated, urogenital gonorrhea with single doses of oral gemifloxacin 320 mg plus oral azithromycin 2 g was associated with cure rates of 99.5% (lower one-sided 95% CI bound = 97.6%), and dual treatment with single doses of intramuscular gentamicin 240 mg plus oral azithromycin 2 g cured 100% of cases (lower one-sided 95% CI bound = 98.5%) <sup id="fnref:569"><a class="footnote-ref" href="#fn:569" rel="footnote">5</a></sup>. This trial was not powered to provide reliable estimates of the efficacy of these regimens for treatment of rectal or pharyngeal infection, but both regimens cured the few extra-genital infections among study participants. Either of these regimens may be considered as alternative treatment options in the presence of cephalosporin allergy. However, gastrointestinal adverse events may limit their use: 7.7% of patients treated with gemifloxacin plus azithromycin and 3.3% of patients treated with gentamicin plus azithromycin vomited within 1 hour of medication administration, necessitating retreatment with a ceftriaxone and azithromycin.</p>
<p>Spectinomycin, which is useful in persons who cannot tolerate cephalosporins, is expensive, has poor efficacy against pharyngeal infection (51.8%; 95% CI=38.7%-64.9%) <sup id="fnref5:566"><a class="footnote-ref" href="#fn:566" rel="footnote">1</a></sup>, and is not being produced in the United States <sup id="fnref:570"><a class="footnote-ref" href="#fn:570" rel="footnote">6</a></sup>. However it has been effective in clinical trials, curing 98.2% of uncomplicated urogenital and anorectal gonococcal infections <sup id="fnref6:566"><a class="footnote-ref" href="#fn:566" rel="footnote">1</a></sup>. When available, spectinomycin is an effective alternative for the treatment of urogenital and anorectal infection. </p>
<p>Monotherapy with azithromycin 2 g orally as a single dose has been demonstrated to be 99.2% effective against uncomplicated urogenital gonorrhea (95% CI = 97.3%–99.9%) <sup id="fnref4:567"><a class="footnote-ref" href="#fn:567" rel="footnote">2</a></sup>. However, monotherapy is no longer recommended because of concerns over the ease with which <em>N. gonorrhoeae</em> can develop resistance to macrolides, and because several studies have documented azithromycin treatment failures <sup id="fnref:546"><a class="footnote-ref" href="#fn:546" rel="footnote">7</a></sup>  <sup id="fnref:571"><a class="footnote-ref" href="#fn:571" rel="footnote">8</a></sup>  <sup id="fnref:572"><a class="footnote-ref" href="#fn:572" rel="footnote">9</a></sup>  <sup id="fnref:573"><a class="footnote-ref" href="#fn:573" rel="footnote">10</a></sup>  <sup id="fnref:574"><a class="footnote-ref" href="#fn:574" rel="footnote">11</a></sup>.  Strains of <em>N. gonorrhoeae</em> circulating in the United States are not adequately susceptible to penicillins, tetracyclines, and older macrolides (e.g., erythromycin), and thus use of these antimicrobials cannot be recommended.</p>
<div class="footnote">
<hr />
<ol>
<li id="fn:566">
<p>Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995;20(Suppl 1):S47–65.&#160;<a class="footnote-backref" href="#fnref:566" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a><a class="footnote-backref" href="#fnref2:566" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a><a class="footnote-backref" href="#fnref3:566" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a><a class="footnote-backref" href="#fnref4:566" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a><a class="footnote-backref" href="#fnref5:566" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a><a class="footnote-backref" href="#fnref6:566" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a></p>
</li>
<li id="fn:567">
<p>Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007;44(Suppl 3):S84–101.&#160;<a class="footnote-backref" href="#fnref:567" rev="footnote" title="Jump back to footnote 2 in the text">&#8617;</a><a class="footnote-backref" href="#fnref2:567" rev="footnote" title="Jump back to footnote 2 in the text">&#8617;</a><a class="footnote-backref" href="#fnref3:567" rev="footnote" title="Jump back to footnote 2 in the text">&#8617;</a><a class="footnote-backref" href="#fnref4:567" rev="footnote" title="Jump back to footnote 2 in the text">&#8617;</a></p>
</li>
<li id="fn:568">
<p>Yu RX, Yin Y, Wang GQ, et al. Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis. PLoS One 2014;9:e87849.&#160;<a class="footnote-backref" href="#fnref:568" rev="footnote" title="Jump back to footnote 3 in the text">&#8617;</a></p>
</li>
<li id="fn:118">
<p>CDC. Sexually transmitted disease surveillance 2013. Atlanta: US Department of Health and Human Services; 2014.&#160;<a class="footnote-backref" href="#fnref:118" rev="footnote" title="Jump back to footnote 4 in the text">&#8617;</a></p>
</li>
<li id="fn:569">
<p>Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014;59:1083–91.&#160;<a class="footnote-backref" href="#fnref:569" rev="footnote" title="Jump back to footnote 5 in the text">&#8617;</a></p>
</li>
<li id="fn:570">
<p>CDC. Discontinuation of Spectinomycin. MMWR Morb Mortal Wkly Rep 2006;55:370.&#160;<a class="footnote-backref" href="#fnref:570" rev="footnote" title="Jump back to footnote 6 in the text">&#8617;</a></p>
</li>
<li id="fn:546">
<p>Ison CA, Hussey J, Sankar KN, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveillance 2011;16:19833.&#160;<a class="footnote-backref" href="#fnref:546" rev="footnote" title="Jump back to footnote 7 in the text">&#8617;</a></p>
</li>
<li id="fn:571">
<p>Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 2012;39:877–9.&#160;<a class="footnote-backref" href="#fnref:571" rev="footnote" title="Jump back to footnote 8 in the text">&#8617;</a></p>
</li>
<li id="fn:572">
<p>Waters LJ, Boag FC, Betournay R. Efficacy of azithromycin 1 g single dose in the management of uncomplicated gonorrhoea. International journal of STD and AIDS 2005;16:84.&#160;<a class="footnote-backref" href="#fnref:572" rev="footnote" title="Jump back to footnote 9 in the text">&#8617;</a></p>
</li>
<li id="fn:573">
<p>McLean CA, Wang SA, Hoff GL, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to azithromycin in Kansas City, Missouri, 1999 to 2000. Sex Transm Dis 2004;31:73–8.&#160;<a class="footnote-backref" href="#fnref:573" rev="footnote" title="Jump back to footnote 10 in the text">&#8617;</a></p>
</li>
<li id="fn:574">
<p>Chisholm SA, Neal TJ, Alawattegama AB, et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009;64:353–8.&#160;<a class="footnote-backref" href="#fnref:574" rev="footnote" title="Jump back to footnote 11 in the text">&#8617;</a></p>
</li>
</ol>
</div>
        </div>
            </div>
        </div>
    </body>
</html>
        